A Phase 2 interventional study of Voclosporin High Dose and Voclosporin Low Dose in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 86 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Lupus Nephritis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Lupus Nephritis · Russian Federation.
Among the 13 studies in Lupus Nephritis with a site in Russian Federation, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 8 in phase 2, and was the 6th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →None of the 13 studies in Lupus Nephritis with a site in Russian Federation is open now. The open studies under Lupus Nephritis, anywhere →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 147 across the 13 interventional studies. Of the 13 that completed or were terminated, 13 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 9 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 8 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Lupus Nephritis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
Voclosporin is a next generation CNI intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current study is to investigate whether voclosporin added to the standard of care treatment in active LN is able to reduce disease activity, as measured by a reduction in proteinuria. Two doses of voclosporin will be studied and compared in a placebo controlled trial on a background of MMF and corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female subjects aged 18 to 75 years.
Diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria.
Kidney within 6 months prior to Screening (Visit 1) with a histologic diagnosis of lupus nephritis (International Society of Nephrology/Renal Pathology Society 2003 classification of lupus nephritis) Classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in combination with Class III or IV.
Laboratory evidence of active nephritis at screening, defined as:
Exclusion Criteria:
Estimated (eGFR) as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation of ≤45 mL/min/1.73 m2.
Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
A previous kidney transplant or planned transplant within study treatment period.
In the opinion of the Investigator, subject does not require long-term treatment (in addition to ).
Current or medical history of:
Other known clinically significant active medical conditions, such as:
Any overlapping condition for which the condition or the treatment of the condition may affect the study assessments or outcomes. Overlapping conditions for which the condition or treatment is not expected to affect assessments or outcomes are not excluded.
Subjects who are pregnant, breast feeding or, if of , not using adequate precautions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Voclosporin, oral, 23.7 mg BID
Drug: Voclosporin Low Dose
Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
Drug: Voclosporin High Dose
Low dose: Voclosporin placebo, oral, 3 capsules BID High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID
Drug: Placebo
Also known as: ISA247
Also known as: ISA247
Number of Subjects Achieving Complete Renal Remission at 24 Weeks
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.
Time frame: week 24
Number of Subjects Achieving Complete Renal Remission at 48 Weeks
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.
Time frame: Week 48
Number of Subjects Achieving Complete Renal Remission at 24 and 48 Weeks in the Presence of Low Dose Steroids
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission. Low-dose steroids is defined as use of ≤5 mg prednisone for 8 weeks leading up to the Week 24 visit date or for 12 weeks leading up to the Week 48 visit date.
Time frame: Weeks 24 and 48
Time to Complete Remission (Number of Weeks)
Time to Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg in the absence of rescue medication.
Time frame: week 48
Time to Sustained Early Complete Remission (Number of Weeks)
Time to Sustained Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.
Time frame: week 48
Number of Subjects Achieving Sustained Early Complete Remission
Sustained early complete remission defined as complete remission that occurred on or before Week 24 and was sustained through Week 48
Time frame: week 48
Time to Partial Remission (Number of Weeks)
Time to partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.
Time frame: week 48
Number of Subjects Achieving Partial Remission
Partial remission is defined as a 50% reduction in UPCR from baseline at Week 24 and Week 48.
Time frame: week 48
Number of Subjects Achieving, and Remaining in, Complete Remission
Sustained complete remission defined as the first occurrence of complete remission that was sustained through Week 48
Time frame: week 48
Duration of Complete Remission (Number of Weeks)
Duration of Complete Remission is defined as time of first occurrence of UPCR ≤ 0.5 mg/mg until the second increase above 0.5 mg/mg (i.e. a single occurrence above 0.5 is permitted) or use of rescue medication.
Time frame: week 48
Number of Subjects Achieving Partial Renal Remission at 24 and 48 Weeks
Number of patients with partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction at week 24 or week 48 in the absence of rescue medication.
Time frame: week 24 and 48
Time to Sustained Partial Remission (Number of Weeks)
Time to sustained partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.
Time frame: week 48
Number of Subjects Achieving Sustained Partial Remission
Sustained partial remission defined as the first occurrence of partial remission that was sustained through Week 48
Time frame: week 48
Time to Sustained Early Partial Remission (Number of Weeks)
Time to sustained early partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.
Time frame: week 48
Number of Subjects Achieving Sustained Early Partial Remission
Early partial remission defined as partial remission that occurred on or before Week 24 and was sustained through Week 48
Time frame: week 48
Change From Baseline in UPCR at Weeks 24 and 48
Change from baseline in urine protein creatinine ratio at weeks 24 and 48
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score
The SELENA-SLEDAI assesses disease activity within the last 10 days. Twenty-four items are scored for nine organ systems, and summed to a maximum of 105 points. A score of 6 is considered clinically significant and indicates active disease. For analysis purposes, a score ≥6 was categorized as "high". The 24 items are as follows: seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, and leukopenia.
Time frame: Baseline, Week 24 and Week 48
| Milestone | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Started | 89 | 88 | 88 |
| Completed | 73 | 80 | 70 |
| Not completed | 16 | 8 | 18 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Death | 10 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 3 |
| Withdrew: Physician decision | 1 | 2 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 5 |
| Withdrew: Refused to follow-up | 1 | 0 | 1 |
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Achieved response | 29 | 24 | 17 |
| Did not achieve response | 60 | 64 | 71 |
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission.
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Achieved response | 44 | 35 | 21 |
| Did not achieve response | 45 | 53 | 67 |
Complete remission is defined as: * Confirmed protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of ≥20%. Subjects who received rescue medication for lupus nephritis or \>10 mg prednisone for \>3 consecutive days or \>7 days total from 56 days prior to remission assessment until the time of the remission assessment were considered not achieving complete remission. Low-dose steroids is defined as use of ≤5 mg prednisone for 8 weeks leading up to the Week 24 visit date or for 12 weeks leading up to the Week 48 visit date.
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Achieved response at week 24 | 26 | 23 | 17 |
| Achieved response at week 48 | 29 | 26 | 18 |
Time to Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg in the absence of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Time to Complete Remission (Number of Weeks) | 19.7 (16.1 to 36.1) | 23.4 (13.7 to 33.4) | NA (48.1 to NA) |
Time to Sustained Complete Remission is defined as time from first dose of voclosporin/placebo to UPCR ≤ 0.5mg occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Time to Sustained Early Complete Remission (Number of Weeks) | NA (20.0 to NA) | NA (NA to NA) | NA (NA to NA) |
Sustained early complete remission defined as complete remission that occurred on or before Week 24 and was sustained through Week 48
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Number of Subjects Achieving Sustained Early Complete Remission | 36 | 22 | 15 |
Time to partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Time to Partial Remission (Number of Weeks) | 4.3 (2.6 to 5.9) | 4.4 (4.1 to 6.1) | 6.6 (4.6 to 8.6) |
Partial remission is defined as a 50% reduction in UPCR from baseline at Week 24 and Week 48.
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Number of Subjects Achieving Partial Remission | 76 | 82 | 67 |
Sustained complete remission defined as the first occurrence of complete remission that was sustained through Week 48
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Number of Participants Achieving Complete Remission | 57 | 61 | 32 |
| Number of Participants Remaining in Complete Remission | 19 | 28 | 10 |
| Number of Participants with Second Increase of UPCR >0.5 mg/mg | 38 | 33 | 22 |
Duration of Complete Remission is defined as time of first occurrence of UPCR ≤ 0.5 mg/mg until the second increase above 0.5 mg/mg (i.e. a single occurrence above 0.5 is permitted) or use of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Duration of Complete Remission (Number of Weeks) | 49 (42.1 to 49.0) | 25 (23.3 to NA) | NA (26.3 to NA) |
Number of patients with partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction at week 24 or week 48 in the absence of rescue medication.
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Achieved partial remission at week 24 | 62 | 58 | 43 |
| Achieved partial remission at week 48 | 61 | 63 | 42 |
Time to sustained partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction sustained until week 48 in the absence of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Time to Sustained Partial Remission (Number of Weeks) | 6.3 (4.0 to 11.9) | 8.1 (6.1 to 16.6) | 26.9 (16.1 to NA) |
Sustained partial remission defined as the first occurrence of partial remission that was sustained through Week 48
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Number of Subjects Achieving Sustained Partial Remission | 61 | 63 | 42 |
Time to sustained early partial Remission is defined as time from first dose of voclosporin/placebo to 50% UPCR reduction occurring at week 24 or earlier and sustained until week 48 in the absence of rescue medication.
| weeks | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Time to Sustained Early Partial Remission (Number of Weeks) | 6.3 (4.0 to 11.9) | 8.1 (6.1 to 16.6) | NA (16.1 to NA) |
Early partial remission defined as partial remission that occurred on or before Week 24 and was sustained through Week 48
| Participants | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Number of Subjects Achieving Sustained Early Partial Remission | 60 | 58 | 36 |
Change from baseline in urine protein creatinine ratio at weeks 24 and 48
| mg/mg | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Baseline UPCR | 5.161 ± 4.151 | 4.476 ± 3.029 | 4.433 ± 3.58 |
| week 24 UPCR | 1.021 ± 1.2369 | 1.356 ± 1.5204 | 2.266 ± 2.8534 |
| CFB at week 24 | -3.769 ± 3.351 | -2.792 ± 2.6207 | -2.216 ± 3.9284 |
| week 48 UPCR | 0.689 ± 0.9172 | 1.101 ± 1.3835 | 1.763 ± 1.9927 |
| CFB at week 48 | -3.998 ± 3.4208 | -2.993 ± 2.6608 | -2.384 ± 3.454 |
The SELENA-SLEDAI assesses disease activity within the last 10 days. Twenty-four items are scored for nine organ systems, and summed to a maximum of 105 points. A score of 6 is considered clinically significant and indicates active disease. For analysis purposes, a score ≥6 was categorized as "high". The 24 items are as follows: seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, and leukopenia.
| score on a scale | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| SELENA-SLEDAI Score at baseline | 12.7 ± 6.37 | 13.9 ± 6.51 | 12.9 ± 6.57 |
| SELENA-SLEDAI Score at week 24 | 6.2 ± 4.53 | 6.5 ± 5.42 | 8.8 ± 5.43 |
| SELENA-SLEDAI Score change from baseline at week 24 | -6.3 ± 5.86 | -7.1 ± 7.41 | -4.5 ± 7.09 |
| SELENA-SLEDAI Score at week 48 | 4.7 ± 5.06 | 5.3 ± 3.97 | 7.8 ± 5.93 |
| SELENA-SLEDAI Score Change from baseline at week 48 | -7.9 ± 6.39 | -8.3 ± 6.93 | -5.3 ± 6.85 |
Collected over Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voclosporin Low Dose | 10/89 (11.2%) | 25/89 (28.1%) | 82/89 (92.1%) |
| Voclosporin High Dose | 2/88 (2.3%) | 22/88 (25%) | 85/88 (96.6%) |
| Placebo | 1/88 (1.1%) | 14/88 (15.9%) | 75/88 (85.2%) |
| Event | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 5/89 | 3/88 | 2/88 |
| Renal Failure AcuteRenal and urinary disorders | 4/89 | 1/88 | 0/88 |
| GastroenteritisInfections and infestations | 1/89 | 2/88 | 1/88 |
| SepsisInfections and infestations | 1/89 | 2/88 | 0/88 |
| Posterior Reversible Encephalitis SyndromeNervous system disorders | 2/89 | 2/88 | 0/88 |
| Systemic Lupus ErythematosusMusculoskeletal and connective tissue disorders | 1/89 | 2/88 | 2/88 |
| HypertensionVascular disorders | 2/89 | 2/88 | 0/88 |
| Urinary Tract InfectionInfections and infestations | 2/89 | 1/88 | 0/88 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/89 | 1/88 | 0/88 |
| Acute Respiratory Distress SyndromeRespiratory, thoracic and mediastinal disorders | 2/89 | 0/88 | 0/88 |
| Event | Voclosporin Low Dose | Voclosporin High Dose | Placebo |
|---|---|---|---|
| Glomerular Filtration Rate DecreasedInvestigations | 27/89 | 27/88 | 12/88 |
| Upper Respiratory Tract InfectionInfections and infestations | 12/89 | 18/88 | 14/88 |
| DiarrhoeaGastrointestinal disorders | 16/89 | 14/88 | 14/88 |
| NauseaGastrointestinal disorders | 16/89 | 11/88 | 7/88 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/89 | 5/88 | 3/88 |
| HeadacheNervous system disorders | 10/89 | 15/88 | 11/88 |
| HypertensionVascular disorders | 15/89 | 14/88 | 8/88 |
| VomitingGastrointestinal disorders | 15/89 | 9/88 | 10/88 |
| AnaemiaBlood and lymphatic system disorders | 13/89 | 14/88 | 7/88 |
| HypokalaemiaMetabolism and nutrition disorders | 12/89 | 12/88 | 9/88 |
| Age, Continuous(years) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 31.4 ± 11.78 | 30.6 ± 9.59 | 33.1 ± 10.03 | 31.7 ± 10.53 |
| Sex: Female, Male(Participants) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 76 | 81 | 73 | 230 |
| Male | 13 | 7 | 15 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 13 | 13 | 35 |
| Not Hispanic or Latino | 80 | 75 | 75 | 230 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 3 | 9 |
| Asian | 52 | 44 | 36 | 132 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 3 | 6 | 5 | 14 |
| White | 30 | 36 | 42 | 108 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| United States | 5 | 10 | 6 | 21 |
| Bangladesh | 17 | 16 | 13 | 46 |
| Belarus | 1 | 8 | 4 | 13 |
| Bulgaria | 2 | 1 | 2 | 5 |
| Ecuador | 2 | 1 | 2 | 5 |
| Georgia | 1 | 1 | 3 | 5 |
| Guatemala | 2 | 6 | 3 | 11 |
| Hong Kong | 0 | 0 | 1 | 1 |
| South Korea | 3 | 2 | 2 | 7 |
| Mexico | 3 | 3 | 8 | 14 |
| Philippines | 20 | 13 | 10 | 43 |
| Poland | 2 | 0 | 2 | 4 |
| Russia | 10 | 9 | 13 | 32 |
| Serbia | 4 | 1 | 7 | 12 |
| Singapore | 0 | 1 | 0 | 1 |
| Spain | 1 | 0 | 0 | 1 |
| Sri Lanka | 5 | 4 | 5 | 14 |
| Taiwan | 2 | 1 | 2 | 5 |
| Thailand | 5 | 6 | 2 | 13 |
| Ukraine | 4 | 5 | 3 | 12 |
| Lupus Nephritis history(years) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Years since diagnosis of LN (years) | 4.2 ± 5.14 | 3.2 ± 4.36 | 3.5 ± 4.03 | 3.7 ± 4.54 |
| Years since first significant proteinuria (years) | 4.5 ± 5.53 | 3.3 ± 4.22 | 3.6 ± 4.06 | 3.8 ± 4.66 |
| Lupus Nephritis history - Baseline UPCR(mg/mg) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Median | 5.16 ± 4.15 | 4.48 ± 3.03 | 4.43 ± 3.58 | 4.69 ± 3.6 |
| Lupus Nephritis history - Baseline eGFR(mL/min/1.73 m2) | Voclosporin Low Dose | Voclosporin High Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 95.3 ± 28.4 | 104 ± 27.3 | 100.2 ± 27.05 | 99.8 ± 27.71 |
The record gives a start of Jun 2014, a primary completion of Jul 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Aurinia Pharmaceuticals Inc.